

Applicants: Robert Reiter and Owen Witte
U.S. Serial No.: 09/038,261
Filed: March 10, 1998
Page 2

Please amend the subject application as follows.

In the Claims:

Please cancel claims 1-43 without prejudice to pursue the subject matter of these claims in a related application.

Please add new claims 44-48 as follows.

Sub C1
--44. (new) A method of inhibiting the growth of prostate tumor cells expressing PSCA, comprising administering to a patient an antibody from the group consisting of a monoclonal antibody designated 1G8 (ATCC No. HB-12612), 3C5 (ATCC No. HB-12616), 2H5 (ATCC No. HB12614), 3E6 (ATCC No. HB12618), or 4A10 (ATCC No. HB-12617) which binds specifically to the extracellular domain of PSCA in an amount effective to inhibit growth of the prostate tumor cells.--

2 --45. (new) The method of claim 44, wherein said antibody is conjugated to a cytotoxic agent.--

3 --46. (new) The method of claim 44, wherein said antibody is conjugated to a radioisotope.--

4 --47. (new) The method of claim 45, wherein said cytotoxic agent is selected from the group consisting of ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, and glucocorticoid.--

A 41